5 EASY FACTS ABOUT TRASTUZUMAB SC DESCRIBED

Probably the most less than-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) reported that the loss of PTEN was observed in 36% of HER2-favourable Main breast tumor specimens from people with stage IV condition. Also, they also showed that people with PTEN-deficient tumors experienced remarkably r